Liraglutide: A bibliographic review
DOI:
https://doi.org/10.33448/rsd-v13i9.46758Keywords:
Liraglutide; Obesity; Weight Loss.Abstract
Introduction: Liraglutide is a compound found in saxenda, an injectable drug, indicated for the treatment of overweight and obesity in adults. Objective: To describe the active mechanism of liraglutide to inform users about the correct use of the drug and its possible side effects. Method: Bibliographic review that used the PUBMED (National Library of Medicine) as a basis for the search for articles. Three descriptors were used in two associations: “liraglutide and obesity” and “(liraglutide obesity) AND (liraglutide effects)”. Results: The association “liraglutide and obesity” allowed the recovery of 45 manuscripts, of which 11 were selected to compose this review. For the association “(liraglutide obesity) AND (liraglutide effects)” 40 results were obtained, and 5 articles were selected. 16 articles were analyzed, and of these, 15 presented an effective result for weight loss. Among the side effects are: nausea, vomiting, diarrhea, constipation. Conclusion: It was observed that the use of liraglutide is relevant for reducing body weight, and that the increase in the amount of drug injected positively interferes with the cholesterol levels of people who use the drug.
References
Bersoux, S., Byun, T. H., Chaliki, S. S., & Poole, K. G. (2017). Pharmacotherapy for obesity: What you need to now. Cleveland Clinic Journal of Medicine, 84(12), 951–958. https://doi.org/10.3949/ccjm.84a.16094
Consultas - Agência Nacional de Vigilância Sanitária. (n.d.). Consultas.anvisa.gov.br. https://consultas.anvisa.gov.br/#/pareceres/q/?nomeProduto=SAXENDA
Consultas - Agência Nacional de Vigilância Sanitária. (2024). Anvisa.gov.br. https://consultas.anvisa.gov.br/#/medicamentos/25351358815201494/?nom
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., Kuchibhotla, U., Moyers, J. S., Benson, C. T., Gimeno, R. E., D’Alessio, D. A., & Haupt, A. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14. https://doi.org/10.1016/j.molmet.2018.09.009
Danne, T., Biester, T., Kapitzke, K., Jacobsen, S. H., Jacobsen, L. V., Petri, K. C. C., Hale, P. M., & Kordonouri, O. (2017). Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. The Journal of Pediatrics, 181, 146-153.e3. https://doi.org/10.1016/j.jpeds.2016.10.076
Dantas, H. L. de L. ., Costa, C. R. B. ., Costa, L. de M. C. ., Lúcio, I. M. L. ., & Comassetto, I. . (2022). Como elaborar uma revisão integrativa: sistematização do método científico. Revista Recien - Revista Científica De Enfermagem, 12(37), 334–345. https://doi.org/10.24276/rrecien2022.12.37.334-345
Fujioka, K., O'Neil, P. M., Davies, M., Greenway, F., C W Lau, D., Claudius, B., Skjøth, T. V., Bjørn Jensen, C., & P H Wilding, J. (2016). Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring, Md.), 24(11), 2278–2288. https://doi.org/10.1002/oby.21629
Htike, Z. Z., Yates, T., Brady, E. M., Webb, D., Gray, L. J., Swarbrick, D., McCann, G. P., Khunti, K., & Davies, M. J. (2016). Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). Cardiovascular Diabetology, 15(1). https://doi.org/10.1186/s12933-016-0421-6
Kolotkin, R. L., Fujioka, K., Wolden, M. L., Brett, J. H., & Bjorner, J. B. (2016). Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical obesity, 6(4), 233–242. https://doi.org/10.1111/cob.12146
Kolotkin, R. L., Gabriel Smolarz, B., Meincke, H. H., & Fujioka, K. (2018). Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. Clinical obesity, 8(1), 1–10. https://doi.org/10.1111/cob.12226
Lambadiari, V., Pavlidis, G., Kousathana, F., Varoudi, M., Vlastos, D., Maratou, E., Georgiou, D., Andreadou, I., Parissis, J., Triantafyllidi, H., Lekakis, J., Iliodromitis, E., Dimitriadis, G., & Ikonomidis, I. (2018). Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovascular diabetology, 17(1), 8. https://doi.org/10.1186/s12933-017-0646-z
le Roux, C., Aroda, V., Hemmingsson, J., Cancino, A. P., Christensen, R., & Pi-Sunyer, X. (2017). Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis. Obesity facts, 10(6), 531–544. https://doi.org/10.1159/000478099
Lee, K.-S., Noh, J., Park, S.-M., Choi, K. M., Kang, S.-M., Won, K.-C., Cho, H.-J., & Moon, M. K. (2023). Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. Diabetes & Metabolism Journal, 47(1), 10–26. https://doi.org/10.4093/dmj.2022.0420
Li, M., Yang, Y., Jiang, D., Ying, M., Wang, Y., & Zhao, R. (2017). Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes. Medicine, 96(39), e8161. https://doi.org/10.1097/md.0000000000008161
Mastrandrea, L. D., Witten, L., Carlsson Petri, K. C., Hale, P. M., Hedman, H. K., & Riesenberg, R. A. (2019). Liraglutide effects in a paediatric (7‐11 y) population with obesity: A randomized, double‐blind, placebo‐controlled, short‐term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Pediatric Obesity, 14(5), e12495. https://doi.org/10.1111/ijpo.12495
Matikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M.-R., & Borén, J. (2018). Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. Diabetes, Obesity and Metabolism, 21(1), 84–94. https://doi.org/10.1111/dom.13487
Mensberg, P., Nyby, S., Jørgensen, P. G., Storgaard, H., Jensen, M. T., Sivertsen, J., Holst, J. J., Kiens, B., Richter, E. A., Knop, F. K., & Vilsbøll, T. (2017). Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes, obesity & metabolism, 19(2), 172–180. https://doi.org/10.1111/dom.12797
Overgaard, R. V., Petri, K. C., Jacobsen, L. V., & Jensen, C. B. (2016). Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis. Clinical Pharmacokinetics, 55(11), 1413–1422. https://doi.org/10.1007/s40262-016-0410-7
Peradze, N., Farr, O. M., Perakakis, N., Lázaro, I., Sala-Vila, A., & Mantzoros, C. S. (2019). Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial. Cardiovascular Diabetology, 18. https://doi.org/10.1186/s12933-019-0945-7
Sharma, A., Ambrosy, A. P., DeVore, A. D., Margulies, K. B., McNulty, S. E., Mentz, R. J., Hernandez, A. F., Michael Felker, G., Cooper, L. B., Lala, A., Vader, J., Groake, J. D., Borlaug, B. A., & Velazquez, E. J. (2018). Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Failure, 5(6), 1035–1043. https://doi.org/10.1002/ehf2.12334
Suélyn, C., Conte, Bolonheis, S., & Campos, D. (2014). Perspectivas de perda de peso com o uso de liraglutida: revisão da literatura perspectives of weight loss with the use of liraglutide: literature review. Brazilian Journal of Surgery and Clinical Research -BJSCR, 9(1), 84–90. https://www.mastereditora.com.br/periodico/20141130_215615.pdf
Tronieri, J. S., Wadden, T. A., Walsh, O., Berkowitz, R. I., Alamuddin, N., Gruber, K., Leonard, S., Bakizada, Z. M., & Chao, A. M. (2020). Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial. International journal of obesity (2005), 44(2), 353–361. https://doi.org/10.1038/s41366-019-0348-6
Tronieri, Jena S., Fabricatore, Anthony N., Wadden, Thomas A., Auerbach, P., Endahl, L., Sugimoto, D., & Rubino, D. (2020). Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial. Obesity Facts, 13(6), 572–583. https://doi.org/10.1159/000511130
Wadden, T. A., Walsh, O. A., Berkowitz, R. I., Chao, A. M., Alamuddin, N., Gruber, K., Leonard, S., Mugler, K., Bakizada, Z., & Tronieri, J. S. (2018). Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial. Obesity, 27(1), 75–86. https://doi.org/10.1002/oby.22359.
Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., & le Roux, C. W. (2016). Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity and Metabolism, 18(5), 491–499. https://doi.org/10.1111/dom.12639
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Nathalia Fernandes de Castro Alves; Bruna Soares de Souza Lima ; Daniel Maciel Rosa; Melissa Drey Araújo Soares ; Kaywindson Nascimento Santos ; Victória Lauton Rabelo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
